Helix Historical Balance Sheet

HBP Stock

CAD 0.87 0.04 4.82%

Trend analysis of Helix BioPharma Corp balance sheet accounts such as Total Current Liabilities of 2.2 M or Property Plant And Equipment Net of 28.2 K provides information on Helix BioPharma's total assets, liabilities, and equity, which is the actual value of Helix BioPharma Corp to its prevalent stockholders. By breaking down trends over time using Helix BioPharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Helix BioPharma Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Helix BioPharma Corp is a good buy for the upcoming year.

Helix BioPharma Inventory

140,220

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Helix Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Helix BioPharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Helix BioPharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Helix BioPharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Helix currently owns. An asset can also be divided into two categories, current and non-current.

Helix BioPharma Balance Sheet Chart

At this time, Helix BioPharma's Deferred Long Term Liabilities is very stable compared to the past year. As of the 30th of November 2024, Current Deferred Revenue is likely to grow to about 416.6 K, while Total Assets are likely to drop about 1.4 M.

Total Assets Total Stockholder Equity Retained Earnings Other Stockholder Equity Property Plant Equipment

Add Fundamental

Total Assets

Total assets refers to the total amount of Helix BioPharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Helix BioPharma Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most accounts from Helix BioPharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Helix BioPharma Corp current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	344K	1.4M	724K	569.3K
Total Assets	3.7M	1.0M	1.5M	1.4M

Other Current Liab Total Assets

Helix BioPharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Property Plant Equipment	Non Currrent Assets Other
Total Assets		-0.07	-0.49	0.96	0.76	-0.95	0.87	-0.51	0.99	0.72	0.99	0.75	-0.69	0.03	0.77	-0.14	-0.16	-0.41	-0.18	1.0	0.13	0.95	0.7	-0.62	0.81	0.54
Other Current Liab	-0.07		-0.05	-0.01	0.17	-0.04	0.13	0.07	-0.12	0.16	-0.12	0.05	0.03	-0.44	0.26	-0.22	0.48	-0.14	0.07	-0.09	0.07	0.09	0.26	-0.22	0.24	0.19
Total Current Liabilities	-0.49	-0.05		-0.7	-0.43	0.66	-0.47	0.75	-0.48	-0.4	-0.48	-0.29	0.28	0.4	-0.23	0.26	0.35	0.96	0.23	-0.48	-0.23	-0.65	-0.12	0.1	-0.3	-0.33
Total Stockholder Equity	0.96	-0.01	-0.7		0.76	-0.98	0.86	-0.64	0.94	0.72	0.94	0.7	-0.64	-0.1	0.71	-0.16	-0.21	-0.64	-0.21	0.95	0.18	0.98	0.64	-0.58	0.77	0.55
Property Plant And Equipment Net	0.76	0.17	-0.43	0.76		-0.73	0.91	-0.22	0.65	0.98	0.65	0.88	-0.78	-0.19	0.84	-0.33	-0.19	-0.43	-0.34	0.7	0.18	0.78	0.58	-0.5	0.82	0.71
Net Debt	-0.95	-0.04	0.66	-0.98	-0.73		-0.85	0.53	-0.94	-0.67	-0.94	-0.65	0.65	0.18	-0.68	0.18	0.15	0.62	0.3	-0.95	-0.17	-0.97	-0.67	0.6	-0.79	-0.49
Retained Earnings	0.87	0.13	-0.47	0.86	0.91	-0.85		-0.31	0.81	0.84	0.81	0.9	-0.9	-0.08	0.74	-0.37	-0.2	-0.45	-0.47	0.84	0.28	0.86	0.62	-0.52	0.87	0.65
Accounts Payable	-0.51	0.07	0.75	-0.64	-0.22	0.53	-0.31		-0.55	-0.23	-0.55	-0.23	0.1	-0.14	-0.23	-0.05	0.23	0.66	-0.26	-0.53	-0.1	-0.61	-0.16	0.14	-0.16	-0.22
Cash	0.99	-0.12	-0.48	0.94	0.65	-0.94	0.81	-0.55		0.6	1.0	0.66	-0.64	0.07	0.67	-0.1	-0.15	-0.4	-0.16	1.0	0.1	0.93	0.67	-0.59	0.75	0.43
Non Current Assets Total	0.72	0.16	-0.4	0.72	0.98	-0.67	0.84	-0.23	0.6		0.6	0.85	-0.71	-0.19	0.87	-0.32	-0.22	-0.4	-0.26	0.65	0.12	0.73	0.52	-0.45	0.74	0.72
Cash And Short Term Investments	0.99	-0.12	-0.48	0.94	0.65	-0.94	0.81	-0.55	1.0	0.6		0.66	-0.64	0.07	0.67	-0.1	-0.15	-0.4	-0.16	1.0	0.1	0.93	0.67	-0.59	0.75	0.43
Net Receivables	0.75	0.05	-0.29	0.7	0.88	-0.65	0.9	-0.23	0.66	0.85	0.66		-0.87	0.15	0.73	-0.3	-0.2	-0.25	-0.37	0.7	0.47	0.71	0.54	-0.45	0.77	0.82
Common Stock Shares Outstanding	-0.69	0.03	0.28	-0.64	-0.78	0.65	-0.9	0.1	-0.64	-0.71	-0.64	-0.87		-0.05	-0.51	0.43	0.4	0.27	0.7	-0.66	-0.34	-0.61	-0.34	0.23	-0.67	-0.56
Non Current Liabilities Total	0.03	-0.44	0.4	-0.1	-0.19	0.18	-0.08	-0.14	0.07	-0.19	0.07	0.15	-0.05		-0.09	0.46	0.06	0.42	0.27	0.06	0.22	-0.11	-0.01	0.04	-0.08	0.07
Inventory	0.77	0.26	-0.23	0.71	0.84	-0.68	0.74	-0.23	0.67	0.87	0.67	0.73	-0.51	-0.09		-0.12	0.17	-0.21	0.04	0.72	0.03	0.77	0.78	-0.71	0.83	0.68
Other Current Assets	-0.14	-0.22	0.26	-0.16	-0.33	0.18	-0.37	-0.05	-0.1	-0.32	-0.1	-0.3	0.43	0.46	-0.12		0.41	0.14	0.39	-0.11	-0.1	-0.15	-0.01	0.01	-0.17	-0.19
Other Stockholder Equity	-0.16	0.48	0.35	-0.21	-0.19	0.15	-0.2	0.23	-0.15	-0.22	-0.15	-0.2	0.4	0.06	0.17	0.41		0.26	0.42	-0.14	0.02	-0.09	0.46	-0.42	0.24	0.0
Total Liab	-0.41	-0.14	0.96	-0.64	-0.43	0.62	-0.45	0.66	-0.4	-0.4	-0.4	-0.25	0.27	0.42	-0.21	0.14	0.26		0.3	-0.4	-0.23	-0.61	-0.12	0.1	-0.3	-0.33
Property Plant And Equipment Gross	-0.18	0.07	0.23	-0.21	-0.34	0.3	-0.47	-0.26	-0.16	-0.26	-0.16	-0.37	0.7	0.27	0.04	0.39	0.42	0.3		-0.16	-0.38	-0.14	0.1	-0.15	-0.24	-0.23
Total Current Assets	1.0	-0.09	-0.48	0.95	0.7	-0.95	0.84	-0.53	1.0	0.65	1.0	0.7	-0.66	0.06	0.72	-0.11	-0.14	-0.4	-0.16		0.13	0.94	0.7	-0.62	0.78	0.49
Intangible Assets	0.13	0.07	-0.23	0.18	0.18	-0.17	0.28	-0.1	0.1	0.12	0.1	0.47	-0.34	0.22	0.03	-0.1	0.02	-0.23	-0.38	0.13		0.15	0.1	-0.08	0.26	0.7
Net Tangible Assets	0.95	0.09	-0.65	0.98	0.78	-0.97	0.86	-0.61	0.93	0.73	0.93	0.71	-0.61	-0.11	0.77	-0.15	-0.09	-0.61	-0.14	0.94	0.15		0.73	-0.67	0.83	0.54
Deferred Long Term Liab	0.7	0.26	-0.12	0.64	0.58	-0.67	0.62	-0.16	0.67	0.52	0.67	0.54	-0.34	-0.01	0.78	-0.01	0.46	-0.12	0.1	0.7	0.1	0.73		-0.98	0.89	0.46
Long Term Investments	-0.62	-0.22	0.1	-0.58	-0.5	0.6	-0.52	0.14	-0.59	-0.45	-0.59	-0.45	0.23	0.04	-0.71	0.01	-0.42	0.1	-0.15	-0.62	-0.08	-0.67	-0.98		-0.81	-0.41
Property Plant Equipment	0.81	0.24	-0.3	0.77	0.82	-0.79	0.87	-0.16	0.75	0.74	0.75	0.77	-0.67	-0.08	0.83	-0.17	0.24	-0.3	-0.24	0.78	0.26	0.83	0.89	-0.81		0.63
Non Currrent Assets Other	0.54	0.19	-0.33	0.55	0.71	-0.49	0.65	-0.22	0.43	0.72	0.43	0.82	-0.56	0.07	0.68	-0.19	0.0	-0.33	-0.23	0.49	0.7	0.54	0.46	-0.41	0.63

Click cells to compare fundamentals

Helix BioPharma Account Relationship Matchups

Helix BioPharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.9M	4.1M	3.7M	1.0M	1.5M	1.4M
Other Current Liab	350K	380K	344K	1.4M	724K	569.3K
Total Current Liabilities	1.9M	3.9M	3.4M	1.9M	1.6M	2.2M
Total Stockholder Equity	2.4M	(1.4M)	319K	(844K)	(90K)	(85.5K)
Property Plant And Equipment Net	246K	47K	35K	33K	29.7K	28.2K
Net Debt	(4.1M)	47K	(784K)	(808K)	(1.1M)	(1.1M)
Retained Earnings	(180.5M)	(188.6M)	(195.1M)	(201.4M)	(210.7M)	(221.2M)
Accounts Payable	1.4M	1.5M	599K	493K	855K	1.1M
Cash	4.2M	3.6M	3.3M	808K	1.1M	1.0M
Non Current Assets Total	246K	47K	35K	33K	29.7K	28.2K
Cash And Short Term Investments	4.2M	3.6M	3.3M	808K	1.1M	1.0M
Net Receivables	180K	353K	280K	62K	54K	51.3K
Common Stock Shares Outstanding	25.5M	27.6M	29.9M	38.6M	44.5M	46.7M
Liabilities And Stockholders Equity	4.9M	4.1M	3.7M	1.0M	1.5M	1.4M
Other Current Assets	245K	100K	443K	126K	321K	203.3K
Other Stockholder Equity	25.5M	27.9M	37.6M	48.5M	52.0M	31.7M
Total Liab	1.9M	5.5M	3.4M	1.9M	1.6M	2.4M
Property Plant And Equipment Gross	246K	1.8M	1.8M	1.8M	1.8M	1.9M
Total Current Assets	4.7M	4.0M	3.7M	996K	1.5M	1.4M
Accumulated Other Comprehensive Income	20.1M	19.6M	10.3M	4.4M	5.0M	2.8M
Net Tangible Assets	(3.3M)	2.4M	(1.4M)	319K	287.1K	272.7K
Property Plant Equipment	246K	47K	36K	33K	29.7K	28.2K
Non Currrent Assets Other	(3.0)	(1.0)	0.0	1K	900.0	855.0
Common Stock	137.3M	139.7M	147.5M	152.1M	158.6M	131.0M
Capital Surpluse	25.5M	27.9M	37.6M	44.1M	50.8M	29.9M
Current Deferred Revenue	38K	124K	301K	345K	396.8K	416.6K
Net Invested Capital	2.4M	2.2M	2.8M	(844K)	(90K)	(85.5K)
Net Working Capital	2.7M	144K	284K	(878K)	(123K)	(129.2K)
Capital Stock	137.3M	139.7M	147.5M	152.1M	158.6M	155.6M

Pair Trading with Helix BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Helix Stock

0.89	THRM	Therma Bright	Pair Corr
0.61	FUND	Katipult Technology Corp	Pair Corr

Moving against Helix Stock

0.71

BHC

Bausch Health Companies

Pair Corr

The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.

The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Helix Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Helix Historical Balance Sheet

Helix BioPharma Inventory

140,220

About Helix Balance Sheet Analysis

Helix BioPharma Balance Sheet Chart

Total Assets

Total Stockholder Equity

Retained Earnings

Helix BioPharma balance sheet Correlations

Helix BioPharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Helix BioPharma balance sheet Accounts

Pair Trading with Helix BioPharma

Moving together with Helix Stock

Moving against Helix Stock

Other Information on Investing in Helix Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Long Term Investments	- 0.98	Deferred Long Term Liab
Net Debt	- 0.98	Total Stockholder Equity
Net Tangible Assets	- 0.97	Net Debt
Total Current Assets	- 0.95	Net Debt
Net Debt	- 0.95	Total Assets
Cash And Short Term Investments	- 0.94	Net Debt